Update Reimbursement Scheme Elvanse®
TBR Nederland hereby informs you that from now on the conditions regarding the Reimbursement Scheme Elvanse® 20 mg, 30 mg, 40 mg, 50 mg, 60 mg and 70 mg will be extended to adults from 18 years old and above indicated for the treatment of attention deficit hyperactivity disorder (ADHD) with pre-existing symptoms of ADHD in childhood.
Conditions
The ELVANSE® Reimbursement Scheme is limited to insured persons aged 6 years or older with ADHD (attention deficit hyperactivity disorder), when the response to previous treatment with methylphenidate proved to be clinically inadequate.